Diverse Biotech Inc, a United States-based biopharmaceutical company, has named Stella Vnook as its new chief executive officer, it was reported yesterday.
Vnook has more than 25 years' experience. She has most recently held senior leadership roles at Assertio Pharma, Jazz Pharmaceuticals, Catalent and Merck. She started her career in Research and Development in the Emergency Department at Temple University Hospital and later continued that work with oncology specialty interest at Temple/Fox Chase Cancer Centre as a pharmacist. Throughout her career she has developed extensive knowledge in many different therapy categories with a particular emphasis on Oncology, Pain Management and Cardiovascular Diseases.
William Fisher, Diverse Biotech's board chairman, said, 'Diverse Biotech is very excited to bring Stella on board as an experienced, knowledgeable, and innovative Senior Leader. Stella will work hand in hand with the current Diverse Biotech Board to continue to build a world class, innovative, experienced Executive Team.'
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA